Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients

Journal of Viral Hepatitis

Volumn 20, Issue SUPPL.1, 2013, Pages 9-17

  Wang, G Q ^a   Ding, Y P ^a   Dong, Y H ^b  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic hepatitis B; HBeAg seroconversion; immune modulatory; Telbivudine

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; LAMIVUDINE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL RECEPTOR NKG2D; PEGINTERFERON; PEGINTERFERON ALPHA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TELBIVUDINE; TENOFOVIR; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG POTENCY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; INNATE IMMUNITY; MACROPHAGE; MEMORY T LYMPHOCYTE; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SEROCONVERSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH17 CELL; TREATMENT DURATION; VIRAL CLEARANCE;

ANTIVIRAL AGENTS; CHINA; CLINICAL TRIALS AS TOPIC; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOMODULATION; THYMIDINE; TREATMENT OUTCOME;

EID: 84874594390     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12059     Document Type: Review

References (80)

1. Rehermann B, Nascimbeni M,. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229. (Pubitemid 40364823)
2. Liaw YF, Gane E, Leung N, et al,. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
3. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF,. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116: 829-834. (Pubitemid 38721324)
4. Lin SM, Yu ML, Lee CM, et al,. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46 (1): 45-52.
5. Niederau C, Heintges T, Lange S, et al,. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427. (Pubitemid 26157437)
6. Yang HI, Lu SN, Liaw YF, et al,. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174.
7. Liaw YF, Leung N, Kao J-H, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283.
8. Marcellin P, Chang TT, Lim SG, et al,. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816. (Pubitemid 36245757)
9. Zeng MD, Mao YM, Yao GB, et al,. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006; 44: 108-116.
10. Chang TT, Gish RG, Man R, et al,. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354 (10): 1001-1010. (Pubitemid 43357804)
11. Yao GB, Chen CW, Lu WL, et al,. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int 2007; 1: 365-372.
12. Marcellin P, Heathcote EJ, Buti M, et al,. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359 (23): 2442-2455.
13. Lau GK, Piratvisuth T, Luo KX, et al,. Peginterferon alfa-2a HBeAg-positive chronic hepatitis B study group. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352 (26): 2682-2695. (Pubitemid 41007823)
14. Hou J, Yin YK, Xu D, et al,. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47: 447-454. (Pubitemid 351280712)
15. Rasenack J, Poynard T, Lai C-L, et al,. Efficacy of telbivudine vs lamivudine at 2 years in patients with HBeAg-positive chronic hepatitis B who are eligible for treatment based on guidelines. J Hepatol 2007; 46 (Suppl. 1): S195.
16. Jia JD, Hou JL, Yin YK, et al,. Two-year results of a phase III comparative trial of telbivudine vs lamivudine in Chinese patients. J Hepatol 2007; 46 (Suppl. 1): S189.
17. Jiang H, Wang J, Zhao W,. Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2013; 32 (1): 11-18.
18. Liaw YF,. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003; 18: 246-252.
19. Chien RN, Liaw YF, Atkins M,. Asian Hepatitis Lamivudine Trial Group. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30 (3): 770-774. (Pubitemid 29409422)
20. Jia J, Gane E, Wang YM, et al,. Prolonged efficacy and safety of 4 years continuous telbivudine treatment in chronic hepatitis B (CHB) patients from GLOBE and 015 studies. Poster FP-090 presented at the 20th Asian Pacific Association for the Study of the Liver (APASL), March 25-28 2010, Beijing, China.
21. Hou J, Xu D, Shi G, et al,. Long-term telbivudine treatment with effective viral control results in resolution of liver fibrosis an inflammation which achieves long-term anti-viral goals in patients with chronic hepatitis B. Hepatol 2011b; 54 (4 Suppl.): 1048A. Poster No. 1446 presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, November 4-8, 2011.
22. Marcellin P, Avila C, Wursthorn K, et al,. Telbivudine (LDT) plus peginterferon (PEGIFN) in HBeAg-positive chronic hepatitis B-very potent antiviral efficacy but risk of peripheral neuropathy (PN). Oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL), Apr 14-18 2010, Vienna, Austria.
23. Piratvisuth T, Komolmit P, Tanwandee T, et al,. 1-year results of telbivudine roadmap study demonstrated maximizing antiviral efficacy and minimizing resistance in HBeAg positive chronic hepatitis B patients. Hepatol Int 2011; 5: 18-19. FC01-01. Oral presentation at the 21st Conference of the Asian Pacific Association of the Study of the Liver (APASL), Feb 17-20 2011, Bangkok, Thailand.
24. Piratvisuth T, Komolmit P, Tanwandee T, et al,. 2-year results of telbivudine roadmap study verify the optimal efficacy and safety results in HBeAg positive chronic hepatitis B patients. J Hepatol 2012; 56 (Suppl. 2): S214.
25. Ren H, Wang YM, Thongsawat S, et al,. Telbivudine induced HBeAg seroconversion is durable during 2 years off-treatment follow up. 2010 APASL Poster Presentation 190.
26. Tsai MC, Lee CM, Chiu KW, et al,. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. J Antimicrob Chemother 2012; 67 (3): 696-699.
27. Dienstag JL, Cianciara J, Karayalcin S, et al,. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37 (4): 748-755. (Pubitemid 36397384)
28. Song BC, Suh DJ, Lee HC, et al,. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32 (4 Pt 1): 803-806.
29. Lee CM, Ong GY, Lu SN, et al,. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 2002; 37 (5): 669-674.
30. Chien RN, Yeh CT, Tsai SL, et al,. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38 (5): 1267-1273.
31. Fung SK, Wong F, Hussain M, et al,. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11 (5): 432-438. (Pubitemid 39336224)
32. Chan HL, Wang H, Niu J, et al,. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007; 12 (3): 345-353. (Pubitemid 46787979)
33. Wu IC, Shiffman ML, Tong MJ, et al,. Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants. Clin Infect Dis 2008; 47 (10): 1305-1311.
34. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al,. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352 (26): 2673-2681. (Pubitemid 41007822)
35. Gish RG, Lok AS, Chang TT, et al,. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133 (5): 1437-1444. (Pubitemid 350029745)
36. Shouval D, Lai CL, Chang TT, et al,. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009; 50 (2): 289-295.
37. Brunetto MR, Moriconi F, Bonino F, et al,. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1145.
38. Lau GK, Marcellin P, Brunetto M, Button T, Batria R,. On-treatment HBsAg decline during peginterferon alfa-2a(40KD) lamivudine in patients with HBeAg-positive CHB as a potential predictor of durable off treatment response. Hepatology 2008; 48 (Suppl. 1): 714A.
39. Moucari R, Mackiewicz V, Lada O, et al,. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157.
40. Moucari R, Korevaar A, Lada O, et al,. High rates of HBsAg seroconversion in HBeAg- positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50: 1084-1092.
41. Wursthorn K, Lutgehetmann M, Dandri M, et al,. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684. (Pubitemid 44433724)
42. Wursthorn K, Jung M, Riva A, et al,. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52: 1611-1620.
43. Neumann AU, Zhou XJ, Boehme RE, et al,. Viral dynamics for LDT (telbivudine)-treated hepatitis B patients: high degree of initial inhibition with dose-dependent second-phase HBV clearance suggests a new model for HBV dynamics. Hepatology 2004; 40 (Suppl. 1): 246A.
44. Wolters LM, Hansen BE, Niesters HG, et al,. The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. J Hepatol 2002; 37 (2): 253-258. (Pubitemid 34833088)
45. Neumann AU, Hepatitis B,. viral kinetics: a dynamic puzzle still to be resolved. Hepatology 2005; 42 (2): 249-254. (Pubitemid 41061074)
46. Neumann AU, Lam NP, Dahari H, et al,. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998 2; 282 (5386): 103-107. (Pubitemid 28471138)
47. Shedlock DJ, Shen H,. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003; 300 (5617): 337-339. (Pubitemid 36433726)
48. Swain SL, McKinstry KK, Strutt TM,. Expanding roles for CD4â T cells in immunity to viruses. Nat Rev Immunol 2012; 12 (2): 136-148.
49. Chisari FV, Ferrari C,. Hepatitis B virus immunopathology. Springer Semin Immunopathol 1995; 17: 261-281.
50. Lin SM, Sheen IS, Chien RN, et al,. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29 (3): 971-975.
51. Evans A, Riva A, Cooksley H, et al,. Programmed death 1expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008; 48: 759-769.
52. Zhang L, Zhang DZ, Chen M, et al,. Dynamic changes of Thl/Th2 type cytokines in peripheral blood of patients with hepatitis B e antigen positive chronic hepatitis B treated with telbivudine. Chin J Hepatol 2009; 17 (3): 175-179. (in Chinese).
53. Wu Z, Yan W, Guo W, et al,. Telbivudine preserves Th1 cytokine and inhibits Th2 cytokine production in MHV-3 induced viral hepatitis model. J Viral Hepatitis 2010; 17 (Suppl. 1): 24-33.
54. Xu D, Fu J, Jin L, et al,. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177 (1): 739-747. (Pubitemid 43939189)
55. Pan XC, Yang F, Cheng M, et al,. The effect of telbivudine on peripheral blood CD4+CD25+ regulatory T cells and its significance in patients with chronic hepatitis B. Chin J Hepatol 2008; 16 (12): 885-888. (in Chinese)
56. Chen T, Yan WM, Ding L, et al,. The combined frequencies of baseline Tregs and NK cells predicted HBV DNA negativity in telbivudine treated HBeAg-positive chronic hepatitis B patients. Hepatology 2011; 54 (4 Suppl.): 1011A.
57. Nan XP, Zhang Y, Yu HT, et al,. Inhibition of viral replication downregulates CD4 + CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B. Viral Immunol 2012; 25 (1): 21-28.
58. Zheng Y, Huang Z, Chen X, et al,. Effects of telbivudine treatment on the circulating CD4(+) T-Cell subpopulations in chronic hepatitis B patients. Mediators Inflamm vol. 2012, Article ID 789859: 9, 2012. doi: 10.1155/2012/789859.
59. Maier H, Isogawa M, Freeman GJ, Chisari FV,. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8 + T lymphocytes in the liver. J Immunol 2007; 178 (5): 2714-2720. (Pubitemid 46333147)
60. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z,. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008; 45 (4): 963-970. (Pubitemid 350019503)
61. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L,. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010; 138 (2): 682-693.
62. Ma SW, Huang X, Li YY, et al,. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol 2012; 56 (4): 775-781.
63. Xie DY, Lin BL, Chen FJ, et al,. Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B. Chinese. Chung Hua Kan Tsang Ping Tsa Chih 2010; 18 (9): 646-650.
64. Fuller MJ, Hildeman DA, Sabbaj S, et al,. Cutting edge: emergence of CD127 high functionally competent memory T cells is compromised by high viral loads and inadequate T cell help. J Immunol 2005; 174 (10): 5926-5930. (Pubitemid 40663777)
65. Paiardini M, Cervasi B, Albrecht H, et al,. Loss of CD127 expression defines an expansion of effector CD8 T cells in HIV-infected individuals. J Immunol 2005; 174 (5): 2900-2909. (Pubitemid 40279708)
66. Sallusto F, Geginat J, Lanzavecchia A,. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Re Immunol 2004; 22: 745-763. (Pubitemid 38680440)
67. Kaech SM, Wherry EJ,. Heterogeneity and cell-fate decisions in effector and memory CD8 T cell differentiation during viral infection. Immunity 2007; 27 (3): 393-405. (Pubitemid 47418674)
68. Lv GC, Ying LJ, Ma WJ, et al,. Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment. Virology Journal 2010; 7: 207.
69. Chen Y, Li X, Ye B, et al,. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Res 2011a; 91 (1): 23-31.
70. Chen T, Ding L, Guo W, et al,. Baseline peripheral NK and its early dynamic changes predicts 24 weeks treatment efficacy in hepatitis B antigen positive chronic hepatitis patients-A single center experience from 54 patients treated with telbivudine (LDT). Hepatology 2010; 52 (2 Suppl.): 564A.
71. Parekh VV, Lalani S, Kim S, et al,. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol 2009; 182 (5): 2816-2826.
72. Emoto M, Kaufmann SH,. Liver NKT cells: an account of heterogeneity. Trends Immunol 2003; 24 (7): 364-369. (Pubitemid 36830962)
73. Chang WS, Kim JY, Kim YJ, et al,. Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 2008; 181 (10): 6707-6710.
74. Shi TD, Zhang JM, Wang XF, Chen M, Sun H, Chen CB, Ren H., Effects of antiviral therapy with telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients. Clin Exp Med 2011; 12 (2): 105-113.
75. Pan XC,. Effect of telbivudine on the function of dendritic cells in patients with chronic hepatitis B. Hepatol Int 2012; 6: 44-66.
76. Pan XC, Yao W, Fu JJ, et al,. Telbivudine improves the function of myeloid dendritic cells in patients with chronic hepatitis B. Acta Virol 2012; 56: 31-38.
77. Gao YQ,. Role of natural killer (NK) cells and toll-like receptor 9 (TLR9) in early responder to telbivudine for chronic hepatitis B patients. Hepatol International 2012; 6: 61.
78. Spolski R, Leonard WJ,. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008; 26: 57-79. (Pubitemid 351600371)
79. Monteleone G, Pallone F, Macdonald TT,. Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci 2009; 30: 441-447.
80. Feng JY, Zhao PW, Jiang YF,. Alterations in CD4 + CXCR5 + TFH cells in different clinical stages of chronic HBV infection. J Hepatology 2011; 54 (Suppl. 1): S120.